BioNTech Keeps Its Buy Ratings as Analysts Trim Price Targets and Clinical Data Cuts Both Ways

Two of Wall Street's most closely watched research houses moved in the same direction on BioNTech this week — and it wasn't toward the exit. Morgan Stanley cut its price target on the German biotech from $114 to $106 on Wednesday while leaving its "Overweight" rating untouched, according to media reports. UBS followed the same playbook, lowering its target from $135 to $125 but keeping its buy recommendation intact. Neither firm abandoned its positive stance; both simply marked their expectations down a notch.

The shares took the adjustments in stride. BioNTech stock added 2.3% in the prior session and was up another 2.2% during the latest trading day.

A Quarter That Cuts Two Ways

The price-target trims landed alongside third-quarter 2026 results that present a mixed financial picture. For the three months alone, BioNTech booked revenue of €1,289.2 million and an IFRS net profit of €184.5 million — a profitable quarter by any measure. Zoom out to the first nine months of 2026, though, and the ledger reads differently: revenue of €1,512.9 million against a net loss of €1,168.2 million.

That gap between a single strong reporting period and the longer trend is precisely what investors must weigh. The quarterly profit counts in BioNTech's favor only to the extent that earnings hold up across subsequent periods; the nine-month shortfall makes that condition hard to ignore.

Management offered some reassurance on the top line. BioNTech raised the lower bound of its full-year revenue guidance from €1,600 million to €1,700 million, while the upper end stayed put at €1,900 million. The company also put its cash, cash equivalents and securities holdings at €16.2 billion.

Breast Cancer Win Comes With an Asterisk

The clinical news that has dominated BioNTech's narrative arrived on October 26, when the company and partner DualityBio reported that the Phase 3 DYNASTY-Breast02 trial met its primary endpoint. Trastuzumab pamirtecan produced a statistically significant improvement in progression-free survival in metastatic HR+/HER2-low breast cancer — but the magnitude of that benefit was moderate.

Overall survival data had not yet matured. Both companies indicated that the available efficacy and safety data pointed to a limited potential benefit in the existing treatment landscape. Hitting an endpoint is one thing; the strength of the effect is another, and both belong in the same assessment of the development program.

Lung Cancer Data Adds a Second Data Point

A day earlier, on October 25, BioNTech and Bristol Myers Squibb published results from the Phase 2 ROSETTA Lung-107 study, which examined pumitamig in combination with docetaxel in advanced non-small cell lung cancer following disease progression on immunotherapy and chemotherapy. Among 30 patients evaluable for efficacy, the confirmed objective response rate came in at 36.7%. Median progression-free survival stood at 6.9 months across the 50 patients treated in total.

That result supplies another clinical argument, though its weight depends on the specific study and patient population involved.

What the Analysts Are Really Saying

Strip away the headlines and the UBS decision carries two distinct signals: continued conviction in the stock, paired with a lower price objective. For investors, that is an invitation to weigh both sides rather than read a single message into the combination — the buy rating speaks for BioNTech, while the reduced target caps the enthusiasm. No specific rationale should be inferred beyond what the firms have disclosed.

The broader case rests on whether the pieces pull in the same direction: a firmer financial base, with the raised revenue floor as its clearest marker, and therapy candidates whose benefits hold up under scrutiny. The positive UBS recommendation, the higher guidance floor and the reached breast cancer endpoint all argue for BioNTech. The nine-month loss and the moderate clinical effect set firm limits. A convincing valuation has to bring both halves together.